Orthofix names new CEO
Global medical device maker Orthofix (NSDQ:OFIX) appointed Bradley Mason president & CEO. Mason is rejoining the company after working as president of the North American division from 2008 to 2009 and as a strategic advisor from 2009 to 2010, when he retired. Mason will be given stock options and a salary of $580,000, according to SEC filings.
Robert Vaters, former CEO, resigned and stepped down from the board of directors. He held the position from August 2011 until his resignation became official on March 12. Company documents stated that the departure was not due to any disagreement.
It has been a tumultuous year for some former Orthofix personnel; the U.S. Justice Dept. recently sentenced former manager Michael McKay with Medicare fraud, the 3rd such sentence connected with the incident.
Read more
Thoratec Corp. gain a board member, loses another
Thoratec (NSDQ:THOR) accepted Elisha Finney’s resignation as a member of the board and chairwoman of the Audit Committee. The day after her resignation notice, the board nominated Todd Schermerhorn to fill the vacancy.
Schermerhorn most recently worked as senior VP and CFO at C.R. Bard, where he retired in 2012. Barring any roadblocks to his election, Schermerhorn will be given the title "audit committee financial expert."
According to company documents, Thoratec has published its Executive Incentive Plan for 2013, which determines the bonuses of the managers and executive officers. For 2013, CEO Gerhard Burbach has a target bonus at $573,628, senior VP David Lehman at $204,345, and VP and CFO Taylor Harris at $154,000.
Read more
Natus appoints CFO
Natus Medical (NSDQ:BABY) named Jonathan Kennedy the new CFO and senior VP, a position currently occupied by Steven Murphy, who will stay on as VP of finance. Kennedy hails from Intersil Corporation, where he served as CFO and corporate controller.
"I am pleased to join Natus during an exciting time in the company’s evolution," Kennedy said in a prepared remarks. "In just a few years, Natus has taken leadership roles in its markets and grown at an extraordinary pace. I look forward to being part of its already successful team."
Read more
Dr. Ellen Strahlman joins BD from GSK
New Jersey-based healthcare company Becton Dickinson & Co. (NYSE:BDX) appointed Ellen Strahlman CMO and senior VP of R&D. Strahlman will also oversee the company’s Medical Affairs and R&D functions. She begins April 22 after closing out her current position as CMO and senior VP at GlaxoSmithKline, a position she has held since 2008.
She has also worked as senior medical advisor of neglected tropical diseases for GSK and has held leadership positions at Merck, Novartis and Pfizer. Strahlman earned her M.D. and M.H.Sc from Johns Hopkins University.
"I am very pleased that Dr. Strahlman will be joining BD at a time when we are strategically focused on driving growth through innovation and customer focus," said BD CEO Vincent Forlenza in prepared remarks. "She brings extensive experience as a senior physician and leader in the pharmaceutical and medical device industries."
Read more
AtriCure takes on a new board member
Cardiac medical devices maker AtriCure (NSDQ:ATRC) appointed Robert White to its board of directors. White, who is currently the president and CEO of a privately owned company called TYRX, will begin serving on the board immediately.
White hails most recently from Medtronic (NYSE:MDT), where he served as president of the spinal treatment business, president of Physio Control and VP of U.S. sales and global marketing. He holds an MBA from Cornel University and a BS in aerospace engineering from the University of Missouri-Rolla.
"Bob has significant leadership experience spanning operations, business development and sales and marketing within the medical device industry, and I believe he will bring significant value to AtriCure and its Board of Directors," said AtriCure CEO Michael Carrel in prepared remarks. "His experience managing and growing several hundred million dollar divisions within Medtronic, and as the current CEO of TYRX, will be incredibly valuable as we seek to further penetrate the AF market. We are thrilled to have him on board."
Read more
